Daiichi Sankyo’s Ken Truitt Joins ImmusanT as Chief Medical Officer

Xconomy Boston — 

Ken Truitt has been appointed chief medical officer of immune drug developer ImmusanT. Truitt comes to the Cambridge, MA, biotech from Daiichi Sankyo, where he was senior vice president for internal medicine therapies. Before joining Daiichi Sankyo, Truitt was director of clinical research in the pulmonary-immunology division of Merck (NYSE: MRK). Last fall, ImmusanT raised $40 million in financing to advance lead drug, NexVax2, into mid-stage studies in celiac disease.